On July 14, Pharmaron (03759.HK) rose 5.59% in regular trading, trading at HK$23.44/share, with turnover of HK$217 million. The rally was driven by the company's H1 earnings forecast disclosed on July 13.

Pharmaron expects H1 revenue of RMB 7.47 billion to RMB 7.66 billion, representing 16%-19% YoY growth. Attributable net profit is forecast at RMB 729 million to RMB 772 million, up 4%-10% YoY. Adjusted non-IFRS net profit is expected at RMB 884 million to RMB 922 million, up 17%-22% YoY. The company attributed the growth to deepening global expansion, with newly signed orders rising over 30% YoY, including small-molecule CDMO orders surging over 50%. Based on mid-range estimates, Q2 revenue grew 19.38% YoY with profitability accelerating sequentially, as Q2 net profit is projected at RMB 394-436 million versus Q1's RMB 335 million, implying 17%-30% QoQ growth.

Notably, Daiwa recently initiated coverage with a Buy rating and HK$25.5 target price, citing recovering global biopharma funding and strong outsourcing demand.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)